Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 14/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690713 | 0.89 | PARP14 (0.47) | PARP14RXFP1BRD4HDAC1 | |
| SCHEMBL32690673 | 0.89 | PARP14 (0.46) | PARP14NPC1RAB9AMAPK8MAPK10 | |
| SCHEMBL32690780 | 0.88 | USP1 (0.42) | MAPTBRD4HDAC1 | |
| SCHEMBL32690851 | 0.84 | NPC1 (0.46) | PARP14NPC1RAB9AMEN1MAPK1 | |
| SCHEMBL32690734 | 0.84 | NPC1 (0.46) | PARP14NPC1RAB9AMEN1MAPK1 | |
| SCHEMBL32690797 | 0.82 | PARP14 (0.42) | PARP14MEN1KMT2AGAAHDAC1 | |
| SCHEMBL32690781 | 0.81 | PARP14 (0.41) | PARP14MEN1KMT2AMAPTGAA | |
| SCHEMBL32690684 | 0.81 | PARP14 (0.41) | PARP14MEN1KMT2AMAPTGAA | |
| SCHEMBL32690701 | 0.81 | PARP14 (0.41) | PARP14MEN1KMT2AMAPTGAA | |
| SCHEMBL32690729 | 0.79 | PARP14 (0.42) | PARP14MEN1KMT2AGAAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | TAIWANJ PHARMACEUTICALS CO LTD (TW) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085046-A1 | Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition | NOX1, NOX4, CYBB | PARP14 583/4885NPC1 2232/4885RAB9A 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.